Biotech IPO window is opening but big pharma M&A still leaders, top bankers say
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Last updated: 2026-06-17 12:53:39 ET
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Elon Musk has a history of setting bold targets and then failing to achieve them . His latest forecasts for SpaceX revenue are more than double what h...
Russell Horwitz, Goldman’s outgoing chief of staff, raised concerns for months about Solomon’s support for Ruemmler, according to the Financial Ti...
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE